Nexia Biotechnologies Inc Company Profile

12:41 EDT 21st October 2016 | BioPortfolio

Until recently Nexia developed and manufactured complex recombinant proteins in the milk of transgenic goats for medical and industrial applications. The Company's two lead programs were Protexia and BioSteelR.On March 7, 2005, Nexia's, shareholders approved the sale of substantially all its operations and assets related to ProtexiaR to PharmAthene (, a privately held biotechnology company focused on the development of biodefense therapeutics, based in Annapolis, Maryland, USA.


P.O. BOX 187Branch Jean-Talon
H1S 2Z2


Phone: 514.586.3942
Fax: 514.371.7880

News Articles [157 Associated News Articles listed on BioPortfolio]

BRIEF-Nexia Health appoints Nick Clemenzi CFO, effective Sept. 29

* Nexia Health appoints new CFO and elects new board at annual shareholders meeting

DGAP-Gesamtstimmrechtsmitteilung: Elanix Biotechnologies AG (deutsch)

Elanix Biotechnologies AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 26a WpHG mit dem Ziel der europaweiten Verbreitung Elanix Biotechnologies AG / Veröffentlichung der Gesamtzahl der....

Avalanche Biotechnologies Closes Transaction With Annapurna Therapeutics and Changes Name to Adverum Biotechnologies

—New Trading Symbol (NASDAQ:ADVM) Effective May 12, 2016— -New Management Team and Additional Board Members in Place- MENLO PARK, Calif., May 12, 2016 (GLOBE NEWSWIRE) -- Avalanche Biotech...

DGAP-Adhoc: Elanix Biotechnologies AG: Vorstand Armin Schulz abberufen (deutsch)

Elanix Biotechnologies AG: Vorstand Armin Schulz abberufen Elanix Biotechnologies AG / Schlagwort(e): Personalie 20.06.2016 18:36 Veröffentlichung einer Ad-hoc-Mitteilung nach § 15 WpHG, übermitte....

BRIEF-Avalanche Biotechnologies Q1 loss per share $0.57

* Avalanche Biotechnologies, Inc. Reports first quarter 2016 financial results

Iris Biotechnologies Announces That the Japanese Patent Office Has Issued a Notice of Allowance ...

Iris Biotechnologies Inc.Simon Chin, 408-806-7149President and

Deals this week: Adverum Biotechnologies, BioLineRx Ltd, Zydus Cadila

Adverum Biotechnologies and Editas Medicine have entered an agreement to explore the delivery of genome editing medicines to treat inherited retinal diseases.

Lifeline Biotechnologies Updates Current Matters

RENO, NV--(Marketwired - Jun 13, 2016) - Lifeline Biotechnologies, Inc. ("The Company") ( OTC PINK : LLBO) updates its shareholders and provides information to Read more...

Drugs and Medications [0 Results]


PubMed Articles [17 Associated PubMed Articles listed on BioPortfolio]

Social Responsibility in Stem Cell Research - Is the News All Bad?

Transparent public discourse about translational stem cell research promotes informed hope about scientific progress and the sustainable development of biotechnologies. Using an a priori coding scheme...

Force fields for simulating the interaction of surfaces with biological molecules.

The interaction of biomolecules with solid interfaces is of fundamental importance to several emerging biotechnologies such as medical implants, anti-fouling coatings and novel diagnostic devices. Man...

Rethinking translational nanomedicine: insights from the 'bottom-up' design of the Porphysome for guiding the clinical development of imageable nanomaterials.

Progress in therapeutics and biotechnologies leveraging new insights in our understanding of cancer biology and progression have had an underwhelming clinical significance thus far. A key challenge ar...

Growth factor therapy sequesters inflammation in affording neuroprotection in cerebrovascular diseases.

In recent years, accumulating evidence has demonstrated the important role of inflammation in cerebrovascular diseases. The inflammation can last for a long period after the initial insult. Hence, mod...

Visceral leishmaniasis: Revisiting current treatments and approaches for future discoveries.

The current treatments for visceral leishmaniasis are old and toxic with limited routes of administration. The emergence of drug-resistant Leishmania threatens the efficacy of the existing reservoir o...

Clinical Trials [0 Results]


Companies [102 Associated Companies listed on BioPortfolio]

Nexia Biotechnologies Incorporated

Nexia Biotechnologies is one of the world's largest producers of authentic recombinant spider silk, and a leading North American animal transgenic company. Nexia manufactures biomaterials and therapeu...

Nexia Biotechnologies Inc

Until recently Nexia developed and manufactured complex recombinant proteins in the milk of transgenic goats for medical and industrial applications. The Company's two lead programs were Protexia and ...

RAN Biotechnologies

Based in Beverly, MA, USA, RAN Biotechnologies, Inc.,, provides chemicals specially optimized for microfluidic and biotechnological applications. Partic...

Nexia Holdings, Inc.

Genemed Biotechnologies Incorporated

Genemed Biotechnologies Inc. provides high quality contract manufacturing services for a wide variety of research and diagnostic products including native or recombinant proteins and nucleotides

More Information about "Nexia Biotechnologies Inc" on BioPortfolio

We have published hundreds of Nexia Biotechnologies Inc news stories on BioPortfolio along with dozens of Nexia Biotechnologies Inc Clinical Trials and PubMed Articles about Nexia Biotechnologies Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Nexia Biotechnologies Inc Companies in our database. You can also find out about relevant Nexia Biotechnologies Inc Drugs and Medications on this site too.

Quick Search

Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Corporate Database Quicklinks

Searches Linking to this Company Record